Miyakawa, Yoshitaka
Imada, Kazunori
Ichikawa, Satoshi
Uchiyama, Hitoji
Ueda, Yasunori
Yonezawa, Akihito
Fujitani, Shigeki
Ogawa, Yoshiyuki
Matsushita, Tadashi
Asakura, Hidesaku
Nishio, Kenji
Suzuki, Kodai
Hashimoto, Yasuhiro
Murakami, Hidenori
Tahara, Sayaka
Tanaka, Tomoyuki
Matsumoto, Masanori http://orcid.org/0000-0002-7243-3126
Clinical trials referenced in this document:
Documents that mention this clinical trial
The efficacy and safety of caplacizumab in Japanese patients with immune-mediated thrombotic thrombocytopenic purpura: an open-label phase 2/3 study
https://doi.org/10.1007/s12185-022-03495-6
Funding for this research was provided by:
Sanofi
Article History
Received: 5 August 2022
Revised: 9 November 2022
Accepted: 9 November 2022
First Online: 24 November 2022
Declarations
:
: YM served as a consultant for Sanofi K.K. and Zenyakukogyo Co., Ltd., has participated in advisory boards for Sanofi K.K., and received research funding from Sanofi K.K. KI received honoraria from Celgene Co., Ltd., Bristol-Myers Squibb K.K., Astellas Pharma Inc., Chugai Pharmaceutical Co., Ltd., Sumitomo Dainippon Pharma Co., Ltd., Otuka Pharmaceutical Co. Ltd., Takeda Pharmaceutical Co. Ltd., Novartis Pharma K.K, Meiji Seika Pharma Co. Ltd., Ono Pharmaceutical Co. Ltd., Janssen Pharmaceutical K.K., Nippon Shinyaku Co., Ltd., and AstraZeneca K.K. SI received honoraria from Sanofi K.K., AstraZeneca K.K, and Chugai Pharmaceutical Co., Ltd. TM served on advisory boards for Takeda Pharmaceutical Co. Ltd. (Baxalta/Shire), Bayer Yakuhin, Ltd., Novo Nordisk Pharma Ltd., Chugai Pharmaceutical Co., Ltd., and Pfizer Inc., received educational and investigational support from Chugai Pharmaceutical Co., Ltd. and Novo Nordisk Pharma Ltd., and received honoraria from Takeda Pharmaceutical Co. Ltd. (Shire), Bayer Yakuhin, Ltd., Sanofi K.K. (Bioverative), Chugai Pharmaceutical Co., Ltd., CSL Behring K.K., Japan Blood Products Organization, KM Biologics Co., Ltd., Kyowa Kirin Co., Ltd., Nichiyaku, Novo Nordisk Pharma Ltd., Octapharma AG, and Sysmex Corporation. MM received honoraria from Asahi Kasei Pharma Corporation, Chugai Pharmaceutical Co., Ltd., and Alexion Pharma Inc., has served as a consultant for Sanofi K.K., Takeda Pharmaceutical Co. Ltd., and Alexion Pharma Inc., received research funding from Asahi Kasei Pharma Corporation and Chugai Pharmaceutical Co., Ltd., and received patents and royalties from Alfesa Pharma Corporation. YH, ST, HM, and TT are currently employed by Sanofi K.K. HU, YU, AY, SF, YO, HA, KN, and KS declare that they have no conflicts of interest.